Updated:
HeartSciences Inc.
HeartSciences Inc. develops AI-enhanced ECG diagnostic software.
HeartSciences Inc.
HeartSciences Inc. is a medical technology company focused on cardiac diagnostics. The firm's core product integrates AI analysis with conventional ECG recordings to identify patterns associated with early-stage heart disease. Public records indicate the company has pursued FDA clearance for its diagnostic platform, targeting the primary care and point-of-care segments rather than replacing specialist cardiology tools. The company's approach is device-agnostic, meaning its software can operate on widely deployed ECG machines. This reduces adoption barriers for hospitals and clinics. Patent filings describe a method of extracting additional data from standard 12-lead ECG signals, emphasizing left ventricular diastolic dysfunction and myocardial ischemia detection. No named portfolio companies or deals have been publicly linked to HeartSciences beyond its own development. HeartSciences has not disclosed workforce size, external offices, or adjacent vehicles. The firm appears to operate as a standalone development-stage entity. No recent operational events from the last 24 months have been captured in public sources. The company's trajectory depends on regulatory milestones and commercial partnerships. HeartSciences differs from full-stack medical device firms by focusing on software overlay rather than hardware. Its business model emphasizes integration into existing clinical workflows, a structural choice that reduces capital intensity but ties revenue to regulatory approvals and reimbursement decisions. Succession and governance structures are not publicly documented.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is HeartSciences' core technology?
HeartSciences applies machine learning algorithms to standard ECG recordings to identify early signs of heart disease, such as left ventricular diastolic dysfunction. The software is designed to work with existing ECG machines, aiming to improve diagnostic yield without new hardware purchases (per public record).
Has HeartSciences received FDA clearance?
Public records show HeartSciences has pursued FDA 510(k) clearance for its AI-ECG platform. The status of that application has not been confirmed through formal agency announcements as of the latest available data (per public record).
Does HeartSciences manufacture its own ECG devices?
No. HeartSciences positions its technology as software that integrates with existing ECG machines from manufacturers like GE or Philips. This device-agnostic approach is a stated structural differentiator (per public record).
What clinical indications does HeartSciences target?
The company's patents and public materials emphasize detection of left ventricular diastolic dysfunction, myocardial ischemia, and other conditions that may not be apparent on a standard ECG reading. The goal is to enable earlier intervention in primary care settings (per public record).
Is HeartSciences venture-backed or publicly traded?
Public records indicate HeartSciences has raised capital through private placements and may be listed on an over-the-counter exchange, but no confirmed investment firm or institutional backer has been independently verified. The capital structure is not fully transparent (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: